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Abstract 
Purpose: The role of the type I receptor tyrosine kinase (HER) family in progression 
of prostate cancer is controversial.  Breast cancer studies demonstrate that these 
receptors should be investigated as a family.  The current study investigates 
expression of HER1-4 and EGFRvIII in matched hormone sensitive and hormone 
refractory prostate tumours. 
Experimental Design:  Immunohistochemical analysis was used to investigate 
protein expression of HER1-4, EGFRvIII and phosphorylated Akt in matched 
hormone sensitive and hormone refractory prostate tumours. 
Results: Surprisingly, high HER2 membrane expression in the hormone sensitive 
tumours was associated with an increased time to biochemical relapse (p=0.0003), 
and this translated into longer overall survival (p=0.0021). Consistent with other 
studies HER4 membrane expression in hormone sensitive tumours was associated 
with longer time to biochemical relapse (p=0.042) and EGFRvIII membrane 
expression was associated with shorter time to biochemical relapse (P=0.015).  An 
increase in phosphorylated Akt expression was associated with reduced survival 
(p=0.0098).  Multivariate analysis demonstrated that HER2 was an independent 
positive predictive marker of time to relapse in hormone sensitive prostate tumours 
(p=0.014).  In contrast, high HER2 expression in the hormone refractory tumours was 
associated with decreased time to death from biochemical relapse (p=0.039), and 
EGFRvIII nuclear expression was associated with decreased time to death from 
biochemical relapse and decreased overall survival (p=0.02 and p=0.005).   
Conclusion: These results suggest that the HER family may have multiple roles in 
prostate cancer and expression of the proteins alone is insufficient to predict the 
biological response that they may elicit. 
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Introduction 
The HER family of receptors comprises 4 members; - EGFR (erbB1/HER 1), HER2 
(erbB2/neu), HER3 (erbB3), and HER4 (erbB4). In addition, variant receptors may be 
generated by alternative splicing (e.g. HER2/4) or mutations (particularly EGFR) and 
overexpression may occur as a result of gene amplification (especially HER2).  The 
most frequently identified mutant form of EGFR is a constitutively active form called 
EGFR variant III (EGFRvIII) (1,2).  The HER receptors play essential roles in 
development and maintenance of mammary, cardiac and neural tissues and have also 
been implicated in the development and progression of many cancers including breast 
and prostate cancer (3,4).   
EGFR, HER3 and HER4 are activated via ligand binding, which results in the 
formation of homo or heterodimers with other family members (4).  As HER2 ligands 
have not been identified, HER2 is believed to be activated by forming heterodimers 
with other family members (3,5).  Formation of HER receptor homo or heterodimers 
results in receptor activation via tyrosine kinase mediated autophosphorylation, 
resulting in phosphorylation and activation of downstream pathways such as the MAP 
kinase cascade and the PI3K/Akt cascade (6). HER3 homodimers, however are unable 
to activate downstream pathways as HER3 lacks intrinsic tyrosine kinase activity and 
is therefore dependent upon formation of heterodimers with other member of the HER 
family (3,4,6).   
Aberrant activation of the HER family may occur via receptor overexpression, 
mutational activation or increased growth factor concentrations.  Increased activation 
of the HER family results in activation of MAP kinase and PI3K/Akt signalling 
cascades, culminating in increased cell proliferation and decreased cell death (3).  It is 
therefore not surprising that modifications to the HER family are strongly associated 
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with tumour formation and progression.  Although the role of the HER family is well 
characterised in breast cancer, with drugs targeting both EGFR and HER2 
demonstrated to be effective in treating metastatic disease, the role of this family in 
the development and progression of prostate cancer remains controversial. 
Data from breast and ovarian cancer suggests that since these receptors have 
similar function, they should be studied as a family.  HER1-3 in breast cancer are 
associated with increased cellular proliferation and HER4 appears to have a non 
proliferative role (7,8).  Breast cancer patients with HER1-3 positive tumours have 
significantly poorer prognosis than those patients with HER negative tumours or 
HER4 positive tumours (9). Therefore in breast cancer HER targeted agents to EGFR 
and HER2 may be a more effective approach than a pan HER inhibitor. 
Increased expression of the EGFR, HER2, HER3, HER4 and EGFRvIII, have all 
been described in prostate cancer (10-14).  Data suggests that there is an increase in 
EGFR and HER2 expression at hormone relapse (10,13,15,16). However since EGFR 
and HER2 genes are not frequently amplified in prostate cancer (12,13), this increase 
was not linked to gene amplification as in other cancers.  Alternatively the cell can 
regulate growth factor receptor expression via receptor degradation.   Following 
ligand stimulation the receptor is internalised where it is either degraded or recycled 
to the cell membrane to undergo further activation (3).  Disruption of this degradation 
process may result in increased protein expression, independent of protein synthesis 
(3).  This may be the mechanism employed in prostate cancer to increase HER2 
expression.  However in the case of EGFR, loss of EGFR protein expression as the 
cancer progresses has been reported and this is accompanied by an increase in 
expression of EGFRvIII (2), resulting in deregulated growth, independent of ligand 
 5 
activation.  An increase in EGFRvIII expression may therefore be more common in 
prostate cancer than an increase in the wild type EGFR. 
HER3 and HER4 are expressed in 11-20% of breast cancers (9), however few 
studies have investigated the role of HER3 and HER4 in prostate cancer.  A recent 
study reported that levels of HER3 and HER4 do not change in the transition from 
HSPC to HRPC.  However high levels of HER4 in the hormone refractory tumours 
was linked to improved patient survival (10), consistent with observations made in 
breast cancer (7,9). 
To our knowledge this is the first report that investigates expression levels of all 
four members of the HER family and EGFRvIII in matched hormone sensitive and 
hormone refractory tissue.  This study aims to clarify the role of the HER family in 
the development of clinical HRPC.  We hypothesis that HER1-3 co-operatively 
mediate hormone relapse and early death in prostate cancer patients.  This study may 
provide evidence to support the use of a novel pan HER inhibitor in treatment of 
prostate cancer or may demonstrate that specific inhibitors of one family member 
would be a more effective approach. 
 
Materials and Methods 
Patient cohort  
Seventy four patients with matched hormone sensitive and hormone refractory tumour 
pairs were retrospectively selected for analysis.  All tumours had patient identification 
removed, including block number and hospital number and were coded to make the 
database anonymous.  Ethical approval was obtained from the Multicentre Research 
Ethics Committee for Scotland (MREC/01/0/36) and Local Research and Ethical 
Committees.  Patients were only selected for analysis if they initially responded to 
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hormone treatment (response was defined by PSA levels falling by at least 50%) but 
subsequently relapsed (2 consecutive rises in PSA greater than 10%) and had a pre 
and post hormone relapse sample available for analysis.  Therefore tumours classed as 
hormone sensitive were from patients that were diagnosed with locally advanced (56) 
or metastatic prostate cancer (18) and received surgery, subsequently followed by 
hormone therapy in the form of androgen deprivation therapy (sub capsular bilateral 
orchidectomy and GnRH analogue) or maximum androgen blockade.  In order to 
meet the inclusion criteria a response to this therapy had to be observed, a response to 
therapy was defined by PSA levels falling by at least 50% and a nadir being reached.  
The hormone sensitive tumour samples were obtained either from a TURP or a TRUS 
guided biopsy.  In addition, patients were required to relapse with hormone refractory 
prostate cancer to meet inclusion criteria.  A tumour was classified as being hormone 
refractory if the patients stopped responding to hormone therapy, this was defined as 2 
consecutive rises in PSA concentration of greater than 10%, the patients were also 
require to fail to respond to any alternative hormone therapies administered.  However 
following identification of such patients, refractory tumour samples were only 
available for analysis if additional surgery was required to treat clinical symptoms 
(bladder outflow obstruction). Therefore hormone refractory tumours samples were 
obtained only by TURP following failure of hormone therapy.  In summary all 
patients in this cohort initially respond to hormone therapy but subsequently relapsed 
with hormone refractory disease, this provides matched hormone sensitive and 
hormone refractory tumours to track molecular changes associated with the transition 
from hormone sensitive to refractory prostate cancer.  Gene amplification status has 
previously been investigated by fluorescent in situ hybridisation for 52 patients in this 
cohort for both EGFR and HER2 (13).  No tumours were amplified for EGFR and 
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only 7% were amplified for HER2 gene.  These were low level amplifications and did 
not correlate with protein expression, it was therefore not deemed necessary to extend 
these studies to the full cohort (13). 
 
Immunohistochemistry 
Specificity of all antibodies used in this study were confirmed by western blotting.  
All immunohistochemistry (IHC) was performed on 5 µm, archival formalin fixed, 
paraffin embedded prostate tumour sections.  EGFR and HER2 IHC was performed as 
previously described (13), in brief, for EGFR IHC tissue was incubated with EGFR 
antibody (clone 31G7, Zymed) at a 1:50 dilution for 1 hour at 25°C and for HER2 
IHC the HercepTestTM (DakoCytomation, Glostrup, Denmark) and a Techmate 
immunostainer (DakoCytomation, Glostrup, Denmark) were used with strict 
adherence to kit protocol.  Immunohistochemistry for EGFRvIII, HER3, HER4 and 
phosphorylated Akt at serine 473 (pAkt) were performed as follows: Antigen retrieval 
for EGFRvIII was performed using heat treatment under pressure in a Tris EDTA 
Buffer (10mM Trizma Base, 0.25mM EDTA) for 5 min. No Antigen retrieval was 
required for HER3 and HER4 and antigen retrieval for pAkt was to heat in Tris 
EDTA Buffer (10mM Trizma Base, 0.25mM EDTA) at 96ºC for 20 minutes.  HER3 
and HER4 were blocked for endogenous biotin using an avidin/biotin blocking kit 
(Vector Labs, UK). Non-specific background staining was blocked using either 5% 
horse serum in TBS for 1 hour (EGFRvIII, pAkt), 2.5% horse serum in TBS for 20 
minutes (HER3) or serum free blocking solution for 10 minutes (DakoCytomation, 
Glostrup, Denmark)(HER4). EGFRvIII (clone ZMD.82, Zymed), HER3 (clone 
H3.105.5, MS-303-PABX, Neomarkers), HER4 (clone HFR1, MS-637-PO, 
Neomarkers) and pAkt (44-622G, Biosource) antibodies were used at 1:50, 1:20, 1:50 
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and 1:100 dilutions, respectively.  EGFRvIII, HER3 and HER4 were incubated for 2 
hours at 25°C and pAkt was incubated overnight at 4°C.  Staining was developed 
using either the LSAB plus kit (DakoCytomation, Glostrup, Denmark) for EGFRvIII 
and HER4, the ImmPRESS Anti-Mouse Ig (peroxidase) Kit (Vector Labs, UK) for 
HER3 and EnVision kit (DakoCytomation, Glostrup, Denmark) for pAkt.. 
Chromagen was detected using DAB (Vector Labs, UK).  A positive and negative 
control slide was included in each IHC run, negative controls were incubated in an 
isotype matched control antibody at a concentration of 1mg/ml.  
Tissue staining intensity was scored blind by 2 independent observers using a 
weighted histoscore method (17) also known as the Hscore system (18). Histoscores 
were calculated from the sum of (1 x % cells staining weakly positive) + (2 x % cell 
staining moderately positive) + (3 x % cells staining strongly positive) with a 
maximum of 300. The inter-class correlation coefficients (ICCC) for each protein was 
calculated to confirm consistency between observers and the mean of the two 
observers’ scores were used for analysis.  Changes in staining between pre and post 
hormone refractory cases were defined as an increase or decrease out with the 95% 
confidence interval for the difference in inter-observer variation i.e. the mean 
difference between the histoscores that each observer assigns for protein expression 
plus 2 standard deviations.  Change in expression of EGFR, HER2, HER3, HER4 and 
EGFRvIII are shown in table 1.   
 
Statistics 
Interclass correlation coefficients were used to confirm consistency between 
observers. Protein expression data was not normally distributed and is shown as 
median and inter quartile ranges.  Wilcoxon Signed Rank Tests were used to compare 
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expression between pre and post hormone refractory tumours. Survival analysis was 
conducted using Kaplan-Meier method and curves were compared with the log-rank 
test.  Multivariate survival analysis and hazard ratios were calculated using Cox 
Regression analysis.  Correlations between HER family members was performed 
using a Spearmans rank test. 
 
Results 
Patient characteristics 
A total of 74 prostate cancer patients (diagnosed between 1984-2000) were included 
in this study with matched hormone sensitive and hormone refractory prostate 
tumours available for analysis (148 tumours in total).  Patients in this cohort were 
diagnosed with locally advanced (56) or metastatic prostate cancer (18) and 
subsequently received surgery and androgen deprivation therapy (28 sub capsular 
bilateral orchidectomy, 48 GnRH analogue, 2 had both).  Fifty eight of the 74 patients 
also received anti androgens therapy in the form of maximum androgen blockade and 
this included all those who received GnRH analogues.  At initial diagnosis the median 
age was 70(67-74) years and 18% of patients had metastasis.  The median time to 
biochemical relapse was 2.35 (1.48-4.40) years, the median PSA at relapse was 17 (6-
41) ng/ml and the percentage of patients with metastasis had increased to 35%.  Sixty-
seven patients died during follow-up and median survival for these patients was 
4.39(3.03-6.86).  Seven patients were alive at last follow-up, the median time of 
follow-up for all 74 patients was 4.38(2.75-6.93) years. 
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Immunostaining 
Membrane protein expression and cytoplasmic protein expression was observed for 
all family members (although expression was very low for EGFR and HER2) (figure 
1, table 1).  Nuclear expression was observed for HER3, HER4 and EGFRvIII (figure 
1, table 1). In order to assess the level of agreement between observers, interclass 
correlation coefficients (ICCC) were calculated for each antibody at each location, all 
ICCC values in this study were greater  >0.7 (which is classed as excellent) (table 1).  
The level of protein expression observed for EGFR and HER2 was lower than that 
observed for HER3, HER4 and EGFRvIII (table 1).  No overall significant increase 
was observed in median protein expression levels for any of the proteins investigated 
in the transition from hormone sensitive to hormone refractory disease (table 1).  
However a significant decrease was observed for HER3 cytoplasmic expression in the 
transition from hormone sensitive to hormone refractory disease (p=0.004, table 1).  
As described in the materials and methods section, a change in protein expression 
between matched hormone sensitive and hormone refractory tumour pairs is defined 
as the mean difference between the histoscores that each observer assigns for the 
protein expression plus 2 standard deviations.  The number of histoscore units that 
represents a change in protein expression between tumour pairs for each protein is 
given in table 1.  Using this definition it was noted that for each protein there were 
sub groups of patients whose tumours exhibited either a fall or rise in protein 
expression (table 1).    
 
Time to biochemical relapse and patient overall survival 
In order to determine if protein expression in the hormone sensitive tumours was 
linked to time to biochemical relapse, Kaplan-Meier graphs of tumours expressing 
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low levels of protein (< 3rd quartile) versus high levels of protein (> 3rd quartile) were 
plotted and compared using the log rank test.  The 3rd quartile was determined as the 
cut off as the medians was not deemed as an appropriate cut-off for EGFR and HER2 
as the medians were very low for both (0 and 2.5 respectively).  However when the 
histograms of score distribution for both proteins were plotted the 3rd quartile 
appeared as the natural cut-off to use.  Therefore in order to keep the cut-offs 
consistent for all proteins the 3rd quartile was employed as the cut-off for all proteins 
in this study.  Using the 3rd quartile as the cut-off neither EGFR nor HER3 expression, 
at any cellular location, was associated with time to biochemical relapse.  However 
those patients whose tumours expressed low levels of HER2 or HER4 in the 
membrane relapsed significantly earlier than those patients whose tumours expressed 
high levels of HER2 or HER4 in the membrane (figure 2a and 2b, p=0.0001 and 
p=0.042, respectively) and this effect translated into a difference in overall survival.  
The median survival for patients whose tumours had low HER2 membrane expression 
is 4.2(2.59-5.81) years compared to 7.27(4.48-10.06) years for patients whose 
tumours expressed high levels (p=0.0021; hazard ratio 0.31(95% C.I. 0.14-0.67)).  
Similarly, the median survival for patients whose tumours expressed low levels of 
HER4 membrane expression is 4.92(3.34-6.50) years compared to 6.44(4.96-7.93) 
years for patients whose tumours had high HER4 expression (p=0.027; hazard ratio 
0.48 (95% C.I. 0.24-0.991)).  HER2 and HER4 expression in the hormone sensitive 
tumour at any other cellular location did not influence time to biochemical relapse or 
overall survival. 
Conversely, patients with tumours that express high levels of membrane EGFRvIII 
relapse significantly earlier than those patients whose tumours expressed low levels of 
membrane EGFRvIII (figure 3, p=0.015). Again this effect translated into overall 
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survival, those patients with tumours expressing high levels of membrane EGFRvIII 
have a median survival period of 3.92(3.02-4.82) years compared to 6.04(4.56-7.52) 
years for those with tumours expressing low membrane EGFRvIII (p=0.037; hazard 
ratio 1.98 (95% C.I. 1.07-3.68)).  Expression of EGFRvIII in the cytoplasm or nucleus 
was not related to time to biochemical relapse, however those patients whose tumours 
expressed high levels of EGFRvIII in the cytoplasm had a significantly shorter 
survival period (4.36(2.68-6.04) years) compared to those patients whose tumours 
expressed low levels of EGFRvIII in the cytoplasm (6.50 (5.48-7.52) years, p=0.012; 
hazard ratio 2.1(95% C.I. 1.15-3.91)). 
Multivariate analysis demonstrated that when expression of EGFR, HER2, HER3, 
HER4 and EGFRvIII is combined with Gleason and presence of metastases at 
diagnosis, only HER2 membrane expression was independently positively associated 
with time to relapse, suggesting that HER2 might be a positive independent predictive 
marker of time to relapse in hormone sensitive tumours (p=0.015). Gleason and 
presence of metastases at diagnosis were negatively associated with time to relapse 
and are known negative prognostic factors in prostate cancer (p=0.020 and 0.031, 
respectively, table 2).  When the same parameters were combined for overall survival, 
only Gleason and presence of metastases at diagnosis were independently associated 
with overall survival (p=0.002 and p=0.045, respectively, table 2). 
 
Time to death from biochemical relapse and patient overall survival 
In order to determine if protein expression in the hormone refractory tumours were 
linked to time to death from biochemical relapse, Kaplan-Meier graphs of tumours 
expressing low levels of protein and high levels of protein were plotted and compared 
using the log rank test.  EGFR, HER3 and HER4 were not significantly associated 
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with time to death from biochemical relapse at any cellular location.  However those 
patients whose tumours expressed high levels of HER2 in the membrane, of the 
hormone refractory tumour died significantly earlier than those patients whose 
tumours expressed low levels of HER2 in the membrane (Figure 4a, p=0.0394; hazard 
ratio 1.6(95% C.I. 0.80-3.19)), this did not however translate into overall survival.  In 
addition, those patients whose tumours expressed high levels of EGFRvIII in the 
nucleus, of the hormone refractory tumour died significantly earlier than those 
patients whose tumours expressed low levels of EGFRvIII in the nucleus (p=0.02; 
hazard ratio 1.4(95% C.I. 0.74-2.65) this effect also translated into overall survival 
(p=0.0059; hazard ratio 2.6 (95% C.I. 1.29-5.49)).   
 
Changes in protein expression with the development of hormone refractory 
disease are associated with patient survival. 
When time to death from biochemical relapse was investigated in relation to an 
increase in protein expression in the transition from hormone sensitive to hormone 
refractory disease it was noted that only an increase in HER2 membrane expression 
was associated with decreased time to death from biochemical relapse (Figure 4b, 
p=0.012; hazard ratio 2.62(95% C.I. 1.2-5.75)).  This effect did not translate into 
reduced overall patient survival and was not observed for any other protein at any 
other location. 
 
Correlation between protein expression of HER family members 
In the hormone sensitive tumours when protein expression levels (expressed as 
histoscore units) were correlated, EGFR protein expression weakly correlates with 
HER2 protein expression (membrane: correlation coefficient=0.342 and p=0.013, 
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cytoplasmic: correlation coefficient=0.397and p=0.004).  EGFR membrane and 
cytoplasmic expression also weakly negative correlates with EGFRvIII cytoplasmic 
expression (membrane: correlation coefficient=-0.285 and p=0.031, cytoplasmic: 
correlation coefficient=-0.286and p=0.031).  In the hormone refractory tumours the 
positive correlation between EGFR and HER2 and the negative correlation between 
EGFR and EGFRvIII are lost.  No other correlations were observed. 
 
Downstream signalling 
In order to establish if the downstream PI3K/Akt pathway is activated in this patient 
cohort, protein expression of activated Akt phosphorylated at serine 473 (pAkt) was 
assessed in those patients with sufficient tumour material remaining for analysis (56 
patients).  Those patients with high pAkt expression in their primary tumours have a 
shorter time to death compared to those patients with low pAkt expression (Figure 5a, 
median overall survival is 3.50(2.52-4.48) years versus 6.04(4.29-7.79) years, 
p=0.058).  Although this did not reach significance, possibly due to the small patient 
number a hazard ratio of 1.7 (95% C.I. 0.97-2.29) was observed.  In addition an 
increase in pAkt expression in the transition from hormone sensitive to hormone 
refractory disease was observed in approximately ¼ of  (13/56) patients, suggesting 
that this pathway is up-regulated in a sub group of patients in the transition from 
hormone sensitive to hormone refractory disease. This increase in expression was 
demonstrated to be associated with reduced patient survival.  Patients with an increase 
in pAkt expression compared to patients with a decrease or no change in expression 
had a reduced survival period from biochemical relapse (median survival falling from 
1.58 to 0.74 years, p=0.050, hazard ratio 1.9 (95% C.I. 0.98-3.68)) and a reduced 
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overall survival (Figure 5b, median survival falling from 5.82 to 3.36 years, 
p=0.0098, hazard ratio 2.3 (95% C.I. 1.2-4.5 )).   
 
Discussion 
Although HER2 has considerable clinical importance in advanced breast cancer (7), 
its role in prostate cancer remains controversial.  In the current study we observed that 
those patients whose tumours had an increase in HER2 expression with the 
development of hormone refractory disease survived for a significantly shorter period 
following biochemical relapse than those patients whose tumours had no change or a 
decrease in HER2 expression, consistent with our previous findings (13).  We also 
observed that those patients whose hormone refractory tumour expressed high levels 
of HER2 die significantly earlier than those with low levels of HER2 expression, 
consistent with Hernes et al. 2004, who also investigated HER2 expression in 
matched prostate cancer patient samples (10).  These results fit with previous breast 
cancer studies that demonstrate that HER2 is linked to increased proliferation and 
decreased apoptosis providing possible mechanisms for disease progression (7,9,19).  
HER2 expression in prostate cancers is also linked with development of metastatic 
prostate cancer and it is possible that patients with high HER2 in their hormone 
refractory tumour represents a sub group of patients at high risk of developing 
metastatic disease, this is also one of the roles demonstrated for HER2 in breast 
cancer (20).  HER2 has also been demonstrated to be required for optimum AR 
activity, therefore inhibition of HER2 may in hormone refractory tumours may be one 
method of inhibiting activation of the AR in the absence of androgens (21) as high 
HER2 expression in hormone refractory prostate cancer tumours appears to be a 
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negative predictive factor for response to therapy, as it is associated with a shorter 
survival period from biochemical relapse (21).   
In contrast to our previous report we found no link between patient outcome and 
an increase in EGFR expression in the transition from hormone sensitive to hormone 
refractory disease (13).  A similar percentage of patients’ tumours were noted to have 
an increase in EGFR protein expression with the development of hormone refractory 
disease (6/74, 8.1% in current study compared to 4/48, 8.3% in previous study), 
however the follow-up is more mature in the current study.  It is difficult to make any 
firm conclusions with so few numbers but it appears that an increase in EGFR 
expression is not linked to decreased patient survival in prostate cancer or impacts on 
a sufficiently small cohort (<10%) that is unlikely to be a valuable target in this 
context.  However high EGFRvIII expression in the hormone sensitive tumours is 
associated with shorter time to biochemical relapse and also shorter overall survival.  
EGFRvIII has a constitutively active tyrosine kinase that signals most frequently via 
the PI3K cascade (22).  Constitutive activation of the PI3K/Akt cascade in 
combination with loss of PTEN commonly observed in prostate cancer results in 
uncontrolled cell proliferation and reduced apoptosis (23).  In the current study an 
increase in expression of phosphorylated and hence activated of Akt is associated with 
a significant reduction in overall patient survival (p=0.0098).  Therefore the current 
study suggests a role of EGFRvIII and PI3K/Akt cascade in progression of prostate 
cancer, this pathway is currently being investigated in this patient cohort.  
Both high HER4 and HER2 protein expression in the HSPC tumours were 
associated with increased time to biochemical relapse and increase overall survival.  
In the normal human prostate epithelium HER4 expression is high and is reported to 
be coupled to differentiation, growth arrest and tumour suppression (14,24).  It is 
 17 
therefore not surprising that when this receptor is expressed in tumour cells, the 
tumour appears to be less aggressive.  When the androgen insensitive prostate cancer 
cell lines DU145 and PC-3 are transfected with HER4, the cells undergo growth arrest 
(24), similar observations are made in breast cancer studies. HER4 transfection in 
breast cells results in reduced proliferation and increased apoptosis (25,26).  In breast 
cancer cells the anti-proliferative role of HER4 correlates with heregulin induced 
HER4 tyrosine phosphorylation (27).   Following degradation of HER4 in breast 
cancer cells by tumor necrosis factor α converting enzyme and presenilin dependent 
gamma secretase the intercellular domain (ICD) of HER4 is released (28).  The ICD 
of HER4 is then able to enter the cytoplasm and accumulate in the mitochondria 
resulting in induction of apoptosis (28), HER4 may function similarly in prostate 
cancer. 
HER2 may also signal for apoptosis following degradation in hormone sensitive 
prostate cancer cells (29). However, it is more likely that HER2 itself is not 
responsible for the mechanism underlying the effect were are observing, as 86% of 
the group of hormone sensitive tumours that express high HER2 levels, express high 
levels of 2 or more family members and 46% have high expression levels of 3 or more 
family members.  In contrast only 10% of low HER2 expressing hormone sensitive 
tumours express high levels of 2 other family members. HER2 may act as a surrogate 
for a subset of tumours with markedly different biology and may not be solely related 
to the function of HER2 itself. 
Different ligands and ligand concentrations can activate the HERs to signal via 
different pathways and induce different biological responses (27).  Specifically, low 
concentrations of heregulin are mitogenic whereas higher concentrations lead to 
differentiation and inhibition of cell growth (27).  This may reflect the most likely 
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explanation of why overexpression of HER2(multiple HERs) is a positive predictive 
factor in hormone sensitive tumours but a negative one in hormone refractory 
tumours.  Heregulin is present in hormone naïve prostate cancer specimens, however 
in prostate cancer specimens from patients that have undergone androgen withdrawal 
heregulin expression is no longer detectable (30).  Heregulin treatment of androgen 
sensitive LNCaP cells which express HER2 and HER3 results in activation of the 
mHOG/p38 pathway, resulting in a significant reduction in cell proliferation and 
morphological changes (cell clustering and increase cell to cell membrane contact) 
consistent with a more differentiated phenotype (14,30).  In contrast treatment of the 
hormone resistant cell line CWR-R1 with heregulin, results in activation of HER2 and 
HER3 which signal via the MAP kinase and PI3K cascades resulting in increase AR 
transactivation and increased proliferation (31).   
In summary, this rigorously controlled study identified EGFRvIII and an increase 
in HER2 expression as prostate cancer risk factors. In contrast high HER4 and 
HER2(multiple HERs) expression in hormone sensitive tumours appeared to have a 
protective role. 
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Table 1  Histoscore variation and comparison of staining intensity for hormone 
sensitive and hormone refractory tumours. 
 HSPC(IQR) HRPC(IQR) P value ICCC Change Fallers Risers 
EGFRm 
EGFRc 
0(0-9) 
0(0-0) 
0(0-18) 
0(0-0) 
0.48 
0.365 
0.89 
0.87 
28 
26 
7% 
1% 
8% 
2% 
HER2m 
HER2c 
2.5(0-30) 
0(0-2.5) 
5(0-22) 
0(0-0) 
0.22 
0.985 
0.91 
0.85 
26 
24 
10% 
6% 
15% 
6% 
HER3m 
HER3c 
HER3n 
85(26-107) 
100(78-136) 
20(0-79) 
75(0-100) 
80(60-100) 
55(1-91) 
0.06 
0.004 
0.349 
0.95 
0.93 
0.95 
48 
49 
34 
32% 
28% 
24% 
14% 
10% 
42% 
HER4m 
HER4c 
HER4n 
63(5-100) 
75(50-100) 
0(0-20) 
40(75-200) 
50(10-160) 
0(0-18) 
0.10 
0.094 
0.501 
0.90 
0.90 
0.91 
48 
47 
32 
27% 
29% 
 
15% 
15% 
14% 
11% 
EGFRvIIIm 
EGFRvIIIc 
EGFRvIIIn 
200(159-255) 
120(100-150) 
130(50-170) 
200(150-225) 
115(100-150) 
70(7.5-150) 
0.09 
0.116 
0.133 
0.82 
0.83 
0.98 
75 
41 
31 
26% 
33% 
20% 
16% 
44% 
31% 
Table 1 shows the median histoscore and interquartile range (IQR) for hormone 
sensitive tumours (HSPC) and hormone refractory tumours (HRPC) and the p value of 
these values compared using a Wilcoxon sign rank test.  The interclass correlation 
coefficient (ICCC) which measures consistence between observers for each protein is 
consistently higher than 0.7 which is classed as excellent.  The mean difference in 
observer scores plus 2 standard deviations is also shown as the number of histoscore 
units that is defined as a change in protein expression (change).  The percentage of 
tumours that were defined as having a fall or rise in protein expression (calculated 
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using the number of histoscore units that is defined as a change in expression) are also 
shown. 
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Table 2 Multivariate analysis 
 Relative 
Hazard Ratio 
(95% C.I.) 
P value 
Time to 
Relaspe 
Relative 
Hazard Ratio 
(95% C.I.) 
P value 
Overall survival 
EGFR 1.37(0.32-5.88) 0.667 1.33(0.18-10) 0.779 
HER2 0.18(0.04-0.76) 0.0155* 0.58(0.12-2.7) 0.482 
HER3 2.5(0.64-9.20) 0.191 1.67(0.34-6.17) 0.604 
HER4 0.75(0.28-2.11) 0.594 0.92(0.32-2.68) 0.880 
EGFRvIII 0.78(0.25-2.50) 0.677 0.68(0.19-2.38) 0.547 
pAkt 1.81(0.63-5.26) 0.269 1.17(0.44-3.12) 0.741 
Gleason 4.68(1.28-12.21) 0.020* 13.2(2.56-69.44) 0.045* 
Mets 4.41(1.15-17.01) 0.031* 4.5(0.99-19.01) 0.002* 
 
Table 2 shows the p values gained for both time to relapse and overall survival when 
expression levels of EGFR, HER2, HER3 HER4, EGFRvIII and phosphorylated Akt 
were combined with Gleason sum and presence of metastasises at diagnosis.  The 
significant values are marked with an *. 
 26 
Figure Legends 
 
Figure 1 Images of hormone refractory tumours stained by standard 
Immunohistochemistry for protein expression of EGFR(A), HER2(B), HER3(C), 
HER4(D) EGFRvIII(E) and  pAkt(F).  Positive staining is brown in colour, membrane 
(M) and cytoplasmic (C) staining for all family members (excluding pAkt) is 
indicated by an arrow and nuclear (N) protein expression for HER3 and HER4 is also 
marked (Magnification x 400).  
Figure 2a shows a Kaplan Meier curve plotted for high (grey) HER2 protein 
expression verses low (black) HER2 protein expression.  Those patients who express 
low levels of HER2 relapse significantly quicker than those who express high levels 
of HER2 (p=0.0003). 
Figure 2b shows a Kaplan Meier curve plotted for high (grey) HER4 protein 
expression verses low (black) HER4 protein expression.  Those patients who express 
low levels of HER4 relapse significantly quicker than those who express high levels 
of HER4  (p=0.042). 
Figure 3 shows a Kaplan Meier curve plotted for high (grey) EGFRvIII protein 
expression verses low (black) EGFRvIII protein expression.  Those patients who 
express high levels of EGFRvIII relapse significantly quicker than those who express 
low levels of  EGFRvIII (p=0.042). 
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Figure 4a shows a Kaplan Meier plot of hormone refractory tumours expressing low 
levels of HER2 (black) versus hormone refractory tumours expression high levels of 
HER2 (grey).  Those patients that expressed high levels of HER2, died significantly 
quicker those patients who expressed low levels of HER2 (p=0.0394). 
Figure 4b shows a Kaplan Meier plot for an increase in HER2 protein expression 
(black) versus no change or a decrease in HER2 protein expression (grey) in the 
transition from hormone sensitive to hormone refractory disease. Those patients with 
an increase in HER2 expression had significantly shorter time to death from 
biochemical relapse compared to those with no change or a decrease in HER2 
expression  (p=0.012).   
Figure 5a shows a Kaplan Meier curve plotted for high (grey) pAkt protein 
expression verses low (black) pAkt protein expression.  Those patients who express 
high levels of pAkt have shorter overall survival than those who express low levels of  
PAkt (p=0.058). 
Figure 5b shows a Kaplan Meier plot for an increase in pAkt protein expression 
(black) versus no change or a decrease in pAkt protein expression (grey) in the 
transition from hormone sensitive to hormone refractory disease. Those patients with 
an increase in pAkt expression had significantly shorter time to death compared to 
those with no change or a decrease in pAkt expression  (p=0.0098).   
 
 
